<DOC>
	<DOC>NCT01140997</DOC>
	<brief_summary>This study is a multi-center, randomized, open-label and positive controlled Phase II Clinical trial to assess the efficacy and safety of Ypeginterferon alfa-2b (with Ribavirin), once a week, in 3 dose-groups respectively, for treatment of Chronic Hepatitis C patients, with Pegasys 180mcg/week &amp; Ribavirin as positive control. It is aimed to establish a dose response and safety relationship sufficient to allow the subsequent design and conduct of Phase III trials, and generate the PK data in hepatitis C patients to satisfy regulatory requirements.</brief_summary>
	<brief_title>Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Age: 18~65 years. Pregnancy tests of female patients must be negative. All patients with effective birth control measures during treatment period and 6 months after the cessation of treatment. Chronic HCV infection evidence: HCV RNA or antiHCV positive &gt;6 months; liver biopsy evidence; vital signs, symptoms, exposure history, and results of laboratory test and iconography examination support diagnosis of chronic hepatitis C. HCV RNAâ‰¥2000IU/ml. Pregnant or lactating women. Mental disorder or physical disability. WBC&lt;3000/mm3, or ANC &lt;1500/mm3, or PLT &lt;90,000/mm3. Received interferon treatment within the previous 6 months or shew no response to interferon. Coinfection with HIV, HAV, HBV, HEV. Evidence of hepatic decompensation. Chest Xray with clinically significant active inflammatory process, history of significant pulmonary disease or any history of interstitial lung disease. History of hypothyroidism or current treatment for thyroid disease. Diabetes mellitus. Uncontrolled significant chronic medical conditions other than chronic hepatitis C or other conditions which in the opinion of the investigator preclude enrollment into the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>HCV</keyword>
	<keyword>CHC</keyword>
	<keyword>Hepatitis C, Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Hepatitis, Chronic</keyword>
	<keyword>Hepatitis, Viral, Human</keyword>
	<keyword>Hepadnaviridae Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Peginterferon alfa</keyword>
</DOC>